Abstract
WAG/Rij rats given placebo showed a depression-like state as compared with normal Wistar rats (lacking convulsive pathology); this was analogous to the state previously seen in rats of this line, with decreased investigative activity in the open field test, increased immobility in the forced swimming test, and decreased consumption and preference for sucrose solution (anhedonia). Chronic administration of the tricyclic antidepressant imipramine (15 mg/kg, i.p., 15 days) had therapeutic (antidepressant) effects on depression-like behavior in WAG/Rij rats. After withdrawal of antidepressant therapy, the behavior of WAG/Rij rats was not significantly different from that of Wistar rats. Acute (single-dose) administration of the selective dopamine D2/D3 receptor antagonist raclopride (100 µg/kg, i.p., 15 min before the start of behavioral testing) increased the symptoms of depression-like behavior and suppressed the antidepressant effect of chronic administration of imipramine in WAG/Rij rats. Raclopride had no significant effect on behavior in Wistar rats. Administration of the dopamine D2/D3 receptor agonist parlodel (a therapeutic form of bromocriptine) cured the depression-like behavior of WAG/Rij rats and had no significant effect on behavior in Wistar rats, with the exception of a reduction in the duration of immobility in the forced swimming test. Imipramine and raclopride had no significant effect on the levels of total movement activity and anxiety in either WAG/Rij or Wistar rats. These results demonstrate the dopamine-dependent nature of depression-like behavior in WAG/Rij rats and show the possible involvement of dopamine D2 receptors in mediating the antidepressant effect of imipramine on genetically determined depression-like behavior in WAG/Rij rats.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
N. A. Krupina, I. N. Orlova, and G. N. Kryzhanovskii, “Effects of parlodel on the development of depressive syndrome in rats evoked by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Byull. Éksperim. Biol. Med., No. 7, 66–70 (1995).
N. A. Krupina, I. N. Orlova, and G. N. Kryzhanovskii, “Effects of melipramine on the development of experimental depressive syndrome in rats evoked by systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Byull. Éksperim. Biol. Med., No. 8, 160–163 (1995).
G. N. Kryzhanovskii, N. A. Krupina, and V. G. Kucheryanu, “A new model of depressive syndrome in rats, evoked by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Byull. Éksperim. Biol. Med., No. 2, 125–128 (1995).
K. Yu. Sarkisova and M. A. Kulikov, “A new experimental model of depression:WAG/Rij rats genetically predisposed to absence epilepsy,” Dokl. Ros. Akad. Nauk., 374, No. 5, 706–709 (2000).
K. Yu. Sarkisova, M. A. Kulikov, and A. B. Shatskova, “Are WAG/Rij rats with genetic predisposition to epilepsy anxious?” Zh. Vyssh. Nerv. Deyat., 55, No. 2, 253–261 (2005).
K. Yu. Sarkisova, I. S. Midzyanovskaya, and M. A. Kulikov, “Depressive-like changes in behavior and expression of the c-fos gene in dopaminergic structures of the brain in WAG/Rij rats,” Zh. Vyssh. Nerv. Deyat., 52, No. 6, 733–742 (2002).
H. Augustsson and B. Meyerson, “Exploration and risk assessment: a comparative study of male house mice (Mus musculus) and two laboratory strains,” Physiol. Behav., 81, No. 4, 685–698 (2004).
D. J. Brunswick, J. D. Amsterdam, P. D. Mozley, and A. Newberg, “Greater availability of brain dopamine transporters in major depression shown by [99mTc]TRODAT-1 SPEC imaging,” Amer. J. Psychol., 160, No. 10, 1836–1841 (2003).
A. M. L. Coenen and E. L. J. M. van Luijtelaar, “Genetic animal models for absence epilepsy: a review of the WAG/Rij strain of rats,” Behav. Genet., 33, 635–655 (2003).
B. Costall, B. J. Jones, M. E. Kelly, R. J. Naylor, and D. M. Tomkins, “Exploration of mice in a black and white test box: validation as a model of anxiety,” Pharmacol. Biochem. Behav., 32, 777–785 (1989).
P. S. D’Aquila, M. Collu, G. L. Gessu, and G. Serra, “The role of dopamine in the mechanism of action of anti-depressant drugs,” Eur. J. Pharmacol., 405, 365–373 (2000).
M. Dziedzicka-Wasylewska, P. Willner, and M. Papp, “Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment,” Behav. Pharmacol., 8, No. 6–7, 607–618 (1997).
N. Garcia-Cairasco, J. A. C. Oliveira, H. Wakamatsu, S. T. Bueno, and F. S. Guimares, “Reduced exploratory activity of audiogenic seizure susceptible Wistar rats,” Physiol. Behav., 64, No. 5, 671–674 (1998).
R. F. Glenn, S. Higgs, and S. J. Cooper, “The effects of 7-OH-DPAT, quinpirole and raclopride on licking for sucrose solutions in the non-deprived rat,” Behav. Pharmacol., 14, No. 8, 609–617 (2003).
G. D. Kuznetsova, E. V. Petrova, A. M. Coenen, and E. L. van Luijtelaar, “Generalized absence epilepsy and catalepsy in rats,” Physiol. Behav., 60, 1165–1169 (1996).
A. Lahmame, C. del Arco, A. Pazos, and M. Yritia, “Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants?” Eur. J. Pharmacol., 337, 115–123 (1997).
K. Mathews, N. Forbes, and I. C. Reid, “Sucrose consumption as a hedonic measure following chronic unpredictable mild stress,” Physiol. Behav., 58, 241–248 (1995).
I. S. Midzianovskaya, G. D. Kuznetsova, A. M. L. Coenen, A. M. Spiridonov, and E. L. J. M. van Luijtelaar, “Electrophysiological and pharmacological characteristics of two types of spike-wave discharges in WAG/Rij rats,” Brain Res., 911, 62–70 (2001).
I. S. Midzianovskaya, A. B. Shatskova, K. Yu. Sarkisova, G. van Luijtelaar, L. Tuomisto, and G. D. Kuznetsova, “Convulsive and nonconvulsive epilepsy in rats: effects on behavioral response to novelty stress,” Epilepsy Behav., 6, 543–551 (2005).
R. Muscat, D. Sampson, and P. Willner, “Dopaminergic mechanism of imipramine action in an animal model of depression,” Biol. Psychol., 28, 223–230 (1990).
R. D. Porsolt and A. Lenegre, “Behavioral models of depression,” in: Experimental Approaches to Anxiety and Depression, J. M. Elliot, D. J. Heal, and C. A. Marsden (eds.), John Willey and Sons, New York (1992), pp. 73–85.
R. Rogos and M. Dziedzicka-Wasylewska, “Effects of anti-depressant drugs on the dopamine D2/D3 receptors in the rat brain differentiated by agonist and antagonist binding-an autoradiographic analysis,” Naunyn-Schmiedeberg’s Arch. Pharmacol., 359, 178–186 (1999).
N. M. Rupniak, “Animal models of depression: challenges from a drug development perspective,” Behav. Pharmacol., 14, No. 5–6, 385–390 (2003).
K. Yu. Sarkisova, I. S. Midzianovskaia, and M. A. Kulikov, “Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG/Rij rats with genetic absence epilepsy,” Behav. Brain Res., 144, 211–226 (2003).
K. Yu. Sarkisova and M. A. Kulikov, “Behavioral characteristics of WAG/Rij rats susceptible and non-susceptible to audiogenic seizures,” Behav. Brain Res., 166, No. 1, 9–18 (2006).
U. Schmitt and C. Hiemke, “Strain differences in open-field and elevated plus-maze behavior of rats without and with pretest handling,” Pharmacol. Biochem. Behav., 59, No. 4, 807–811 (1998).
R. N. Walsh and R. A. Cummins, “The open field test: a critical review,” Psychol. Bull., 83, 482–504 (1976).
P. Willner, R. Muscat, and M. Papp, “Chronic mild stress-induced anhedonia: a realistic animal model of depression,” Neurosci. Biobehav. Rev., 16, 525–534 (1992).
P. Willner and P. J. Mitchell, “The validity of animal models of predisposition to depression,” Behav. Pharmacol., 13, 169–188 (2002).
P. Willner, A. S. Hale, and S. Argyropoulos, “Dopaminergic mechanism of antidepressant action in depressed patients,” J. Affect. Disord., 86, No. 1, 37–45 (2005).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Zhurnal Vysshei Nervnoi Deyatel’nosti imeni I. P. Pavlova, Vol. 57, No. 1, pp. 91–102, January–February, 2007.
Rights and permissions
About this article
Cite this article
Sarkisova, K.Y., Kulikov, M.A., Midzyanovskaya, I.S. et al. Dopamine-dependent nature of depression-like behavior in WAG/Rij rats with genetic absence epilepsy. Neurosci Behav Physi 38, 119–128 (2008). https://doi.org/10.1007/s11055-008-0017-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11055-008-0017-z